Key result
Blood biomarkers, including inflammatory cytokines and microRNAs, offer noninvasive means to improve the diagnosis, prognosis prediction, and management of patients with arrhythmogenic cardiomyopathy.
Blood-based biomarkers, including genetic, inflammatory, and myocardial markers, hold promise for improving the noninvasive diagnosis and management of arrhythmogenic cardiomyopathy.
Blood, serum and plasma represent accessible sources of data about physiological and pathologic status. In arrhythmogenic cardiomyopathy (ACM), circulating nucleated cells are routinely used for detection of germinal genetic mutations. In addition, different biomarkers have been proposed for diagnostic purposes and for monitoring disease progression, including inflammatory cytokines, markers of myocardial dysfunction and damage, and microRNAs. This review summarizes the current information that can be retrieved from the blood of ACM patients and considers the future prospects. Improvements in current knowledge of circulating factors may provide noninvasive means to simplify and improve the diagnosis, prognosis prediction, and management of ACM patients.
No takes yet. Share an insight, caveat, or question.
Stadiotti et al. (2018) conducted a review in Arrhythmogenic cardiomyopathy (ACM). Blood biomarkers was evaluated. Blood biomarkers, including inflammatory cytokines and microRNAs, offer noninvasive means to improve the diagnosis, prognosis prediction, and management of patients with arrhythmogenic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: